TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.
Mosti is using Budget 2026 to advance its 'From Lab to Livelihood' agenda as a catalyst for national economic growth and innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback